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Abstract
Introduction: Metastasis is a common event and the main cause of death in cancer patients. Lymphangiogenesis
refers to the formation of new lymphatic vessels and is thought to be involved in the development of metastasis.
Sunitinib is a multi-kinase inhibitor that blocks receptor tyrosine kinase activity, including that of vascular
endothelial growth factor receptors (VEGFRs). Although sunitinib is a clinically available angiogenesis inhibitor, its
effects on lymphangiogenesis and lymph node metastasis remain unclear. The purpose of this study was to
investigate the effects of sunitinib on vascular endothelial growth factor receptor 3 (VEGFR-3) and a related event,
lymphangiogenesis.
Methods: The effects of sunitinib on the degree of phosphorylation of VEGFR-2/3 and other signaling molecules
was examined in lymphatic endothelial cells (LECs) treated with the drug; VEGF-induced LEC growth, migration,
and tube formation were also examined. For the in vivo study, luciferase-expressing breast cancer cells were
transplanted into mammary fat pads of mice; the microvessel and lymphatic vessel density was then measured
after treatment with sunitinib and anti-VEGFR-2 antibody.
Results: First, in human LECs, sunitinib blocked both VEGFR-2 and VEGFR-3 phosphorylation induced by VEGF-C or
VEGF-D, and abrogated the activation of the downstream molecules extracellular signal-regulated kinase 1/2 (ERK1/2)
and Akt. Furthermore, sunitinib attenuated the cell-proliferation activity induced by VEGF-C/D and prevented VEGF-C-
induced migration and tube formation of the LECs; however, anti-VEGFR2 treatment shows only a partial effect on
the growth and functions of the LECs. We used a breast cancer cell line expressing luciferase as a metastatic cancer
model. Sunitinib treatment (40 mg/kg/day) inhibited the growth of the primary tumor transplanted in the mammary
fat pad of the mice and significantly reduced the number of blood and lymphatic vessels in the tumor. Furthermore,
the development of axillary lymph node metastasis, detected by bioluminescent imaging, was markedly suppressed.
This effect of sunitinib was more potent than that of DC101, an anti-mouse VEGFR-2 antibody.
Conclusions: The results suggest that sunitinib might be beneficial for the treatment of breast cancer by
suppressing lymphangiogenesis and lymph node metastasis, through inhibition, particularly important, of VEGFR-3.
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Metastasis is the main cause of therapeutic failure and
death in cancer patients [1]. Tumor cells disseminate to
distant organs through lymphatic vessels and blood ves-
sels [2]. The status of metastasis to the regional lymph
nodes is a prognostic factor in patients with malignancies
and a determinant of the treatment course of patients
[3]. Lymph nodes have also been proposed to serve as a
cancer cell reservoir, providing a supportive environment
for further movement of the cancer cells to distal organs
[4,5]. Previously, this metastatic process was thought to
be passively initiated via preexisting lymphatic vascula-
ture; however, recent studies suggest that new lymphatic
vessel formation, called lymphangiogenesis, actively con-
tributes to lymphatic metastasis. In a clinical study, lym-
phatic vessel density in a tumor was correlated with the
risk of lymph node metastasis and a poor prognosis [6].
Therefore, therapies targeting tumor lymphangiogenesis
are expected to suppress the risk of development of
metastasis and provide clinical benefit in cancer patients.
The lymphangiogenic process is regulated by numerous
molecules, including the vascular endothelial growth fac-
tor (VEGF) and VEGF receptor (VEGFR) family. Among
them, VEGF-C and VEGF-D are well-studied potent
inducers of lymphangiogenesis [7]. A large number of
clinical studies have demonstrated that the expression
levels of VEGF-C/VEGF-D are markedly associated with
lymphangiogenesis and lymph node metastasis in various
types of cancers, including breast, ovarian, lung, and
colon cancer [8]; their forced expression in cancer cells
was shown to induce tumor lymphangiogenesis and
lymph node metastasis in a preclinical model [9,10]. In
in vitro analyses, VEGF-C and VEGF-D have been shown
to induce various cellular functions of the lymphatic
endothelial cells (LECs) that constitute lymphatic capil-
laries. These cellular functions include proliferation,
migration, and tube formation, which are important for
lymphatic vascular development [11,12]. Their receptors,
VEGFR-2 and VEGFR-3, are tyrosine kinase receptors,
and under VEGFC/D stimulation, undergo autopho-
sphorylation and activate the downstream molecules Akt
and extracellular signal-regulated kinase1/2 (ERK1/2)
[13].
VEGFR-3 is expressed in all endothelial cells and is
necessary for the formation of the primary vascular
plexus in early development; subsequently, its expression
becomes restricted, with the exception of the fenestrated
blood vessels, to LECs [5]. The results of experimental
studies indicate that VEGFR-3 signaling plays a key role
in the development of the lymphatic vascular network
[14,15]. VEGFR-2 is a well-known mediator of blood
vessel formation and has been shown to be expressed in
the LECs and lymphatic endothelium in vivo [16,17].
Furthermore, VEGFR-2 and VEGFR-3 form homodimer
and heterodimer complexes in the LECs and exhibit
cooperative and redundant functions in adult lymphan-
giogenesis [18].
Targeting of VEGF and VEGFR signaling in a tumor
has been considered a therapeutic strategy. To achieve
this, several approaches have been examined, including
use of antibodies against VEGF receptors [19,20], soluble
receptors [21], and small molecules [22-24]. In particular,
multitargeting of small molecules has been reported to
be highly effective in animal models. Given the complex-
ity and redundancy of the VEGF signaling network, mul-
titargeting may be a better strategy for effective
inhibition of lymphangiogenesis.
Before this approach, angiogenesis inhibitors targeting
the VEGF-A and VEGFR-2 signaling pathways were devel-
oped [25]. Sunitinib and bevacizumab are already
approved angiogenesis inhibitors available for the treat-
ment of renal cell carcinoma and metastatic gastrointest-
inal stromal tumors that prove resistant to imatinib.
Sunitinib inhibits receptor tyrosine kinase activity, includ-
ing that of VEGFR, PDGFR, KIT, FLT3, RET, and CSF1R.
Although one of the main mechanisms underlying tumor
growth inhibition by sunitinib appears to be its antiangio-
genic activity exerted via its inhibitory action on VEGFR2
kinase activity in blood endothelial cells, its influence on
lymphatic cell functions and tumor lymphangiogenesis
remains unclear.
In this study, we evaluated the effect of sunitinib on
lymphangiogenesis and lymph node metastasis. For this
purpose, we used lymphatic dermal endothelial cells for
in vitro analyses with the endogenous ligands VEGF-C
and VEGF-D. To examine lymphangiogenesis in vivo,
MDA-MB-231luc-D3H2LN (MDA-MB-231LN), a
daughter cell line of the metastatic breast cancer MDA-
MB-231, was used along with the bioluminescent ima-
ging technology. We found that sunitinib inhibited
VEGFR-2 and VEGFR-3 activity simultaneously, thereby
inhibiting the cellular functions of the LECs, including
proliferation, migration, and tube formation. In addition,
it attenuated tumor lymphangiogenesis and lymph node
metastasis in a mouse mammary fat pad (m.f.p.) model.
This is the first article reporting that sunitinib, which is a
clinically available angiogenesis inhibitor, blocks VEGFR-
3 signaling in LECs to suppress lymphangiogenesis.
Materials and methods
Reagents and cells
Sunitinib (Symansis, Washdyke, New Zealand, and Pfi-
zer, New York, NY) was resuspended in dimethyl sulfox-
ide (DMSO) and diluted in cell medium or PBS for the
in vitro and in vivo assays. Recombinant human VEGF-
C and VEGF-D were dissolved in sterile PBS containing
Kodera et al. Breast Cancer Research 2011, 13:R66
http://breast-cancer-research.com/content/13/3/R66
Page 2 of 110.1% bovine serum albumin and stored at -80°C. The
following antibodies were used: mouse monoclonal
VEGFR-3 and phosphotyrosine (Upstate Biotechnology,
Inc., Lake Placid, NY), ERK1/2, phospho-ERK1/2, Akt,
phospho-Akt, c-Raf, phospho-c-Raf, MEK, phospho-
MEK (Cell Signaling Technology, Beverly, MA), ras
(abcam), CD31 (BD Pharmingen, San Jose, CA), lympha-
tic vessel endothelial hyaluronan receptor LYVE-1
(Upstate Biotechnology), and neutralizing VEGFR-2
antibody (R&D Systems, Minneapolis, MN). LECs were
purchased from Lonza (Gaithersburg, MD) and main-
tained in EGM-2 according to the supplier’si n s t r u c -
tions. Cancer cell lines were purchased from the
American Type Culture Collection (Manassas, VA). The
MDA-MB-231luc-D3H2LN (MDA-MB-231LN) cell line
was obtained from Caliper (Hopkinton, MA). An MDA-
MB-231LN cell line stably expressing luciferase protein
was established and maintained as described in [26].
Immunoprecipitation and Western-blot analysis
Cells were cultured overnight in a serum-free medium. The
medium was replaced with a medium containing DMSO or
sunitinib for 2 hours, and the cells were then stimulated
with VEGF-C/D for 10 minutes. Cells were rinsed with
cold PBS and lysed with RIPA buffer (25 mM Tris HCl (pH
7.6), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS, phosphatase inhibitor cocktail (Sigma, Saint
Louis, MO), and complete protease inhibitor (Roche, India-
napolis, IN)). For detection of phosphorylated VEGFR-3,
cell lysates were immunoprecipitated with anti-VEGFR-3
and then pulled down with protein G (Santa Cruz Biotech-
nology, Santa Cruz, CA). Samples were dissolved in SDS
sample buffer and electrophoresed on 10% SDS-PAGE gel
before being transferred to a PVDF membrane. To detect
downstream signaling, confluent LEC cultures were stimu-
lated and harvested as described. The same amounts of
lysates were separated by 12% SDS-PAGE and then blotted
onto a PVDF membrane. Phosphorylated proteins were
detected with the respective antibodies, as described earlier.
After detection, the antibodies were removed with stripping
buffer (Pierce, Rockford, IL), and the membranes were
reblotted with anti-ERK1/2 and anti-Akt.
LEC proliferation assay
To evaluate the effect of inhibitors and antibodies on
LEC growth, we used the MTS assay, as previously
described [27]. In brief, a 200-μl volume of an LEC cell
suspension was seeded into each well of a 96-well plate
(3,000 cells/well). The cells were cultured overnight
before the medium was replaced with a serum-free med-
ium containing growth factors and inhibitors. The con-
centrations of VEGF-C and VEGF-D were 500 ng/ml.
The cells were exposed to each drug at various concen-
trations and cultured at 37°C in a humidified
atmosphere for 72 hours. After the culture period, 40 μl
of MTS solution was added to each well, and the plates
were incubated for a further 4 hours at 37°C. The
growth-inhibitory effects of each drug were assessed
spectrophotometrically (Spectra Max 190; Molecular
Devices Corporation, Sunnyvale, CA). The results were
evaluated with analysis of variance (ANOVA).
LEC migration assay
LECs were suspended in a serum-free medium and seeded
in the top chamber of a cell-culture insert (BD Biosciences,
Bedford, MA) with DMSO or sunitinib. The inserts were
placed in 24-well plates and incubated with medium con-
taining VEGF-C for 24 hours. The migrated cells were
fixed with glutaraldehyde and stained with crystal violet.
The cell numbers were counted under a microscope, and
relative migration was evaluated by dividing the number of
sunitinib-treated cells by the number of control cells.
Tube-formation assay
LECs were trypsinized and resuspended in a serum-free
medium and then seeded on culture plates (2 × 10
4
cells/well). After overnight culture, collagen I gel (3 mg/
ml) was layered on the plated cells containing DMSO,
sunitinib, or anti-VEGFR2. Cells were incubated for 16
hours at 37°C, in a 5% CO2 atmosphere.
Quantification of the secreted protein (ELISA)
Cancer cells were cultured in a 12-well plate (1.2 × 10
5)
with basal medium containing 0.1% bovine serum albu-
min for 24 hours. The amount of secreted VEGF-A,
VEGF-C, and VEGF-D in the cultured medium was
quantified by using ELISA detection kits (R&D Systems).
The m.f.p. model
MDA-MB-231LN was trypsinized and resuspended in a
50% DPBS/50% matrigel. The cells were implanted into
the left abdominal m.f.p. site of 6- to 7-week-old SCID
mice. Five days after the transplantation, the mice were
randomized and divided into the control and treatment
groups. Depending on the group to which they belonged,
the mice were orally administered either vehicle or suniti-
nib once a day for 2 weeks. Tumor volumes were mea-
sured with calipers every 3 or 4 days. After 2 weeks, the
lymph node metastasis status was evaluated. All animal
experiments were conducted with the approval of the
Committee for Ethics in Animal Experimentation, and in
accordance with the Guidelines for Animal Experiments
of National Cancer Center.
Immunohistochemical analysis of angiogenesis and
lymphangiogenesis
After treatment, the tumors were excised and embedded
in OCT compound. Six-micrometer-thick frozen
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clonal antibody; BD Pharmingen) for blood vessels and
antibody to LYVE-1 (rabbit polyclonal antibody; Upstate
Biotechnology) for lymphatic vessels. Each type of vessel
was visualized with EnVision Detection System (DAKO,
Glostrup, Denmark) and counted as the number of
structures per square millimeter. Three sections from
five individual mice were evaluated and then statistically
analyzed by using the Dunnett method.
Evaluation of lymph node metastasis
Metastasis in the axillary lymph nodes was detected by
using the IVIS Imaging System (Xenogen, Alameda,
CA). At 10 to 15 minutes after luciferin injection, the
mice were placed in the IVIS Imaging System and
imaged in the ventral view. To confirm the presence of
metastatic cancer cells, the lymph nodes and lungs were
excised from the mice at necropsy and imaged ex vivo.
Data were evaluated with the Dunnett multiple
comparisons.
Statistics
All data are presented as mean ± standard deviation.
Results were considered statistically significant at P < 0.05.
Results
Sunitinib inhibited VEGFR-2 and VEGFR-3 signaling
To investigate the mechanism by which sunitinib inhib-
ited lymphangiogenesis, we first used lymphatic vascular
endothelial cells. Both VEGFR-2 and VEGFR-3 are
expressed in LECs and are significantly phosphorylated
by their natural ligands, VEGF-C and VEGF-D (Figure
1a, b). The receptor-activation potential of VEGF-C is
higher as compared with that of VEGF-D. Sunitinib treat-
ment suppressed these phosphorylations in a dose-
dependent manner (IC50 =4 8n M). Sunitinib at similar
concentrations has also been reported to inhibit VEGFR-
3 in a cell-free kinase assay [25]. Taken together, suniti-
nib is actually an inhibitor of both VEGFR-2 and
VEGFR-3 in the LECs. Phosphorylated VEGFRs are con-
sidered to mediate cellular functions by activating various
types of signaling pathways. ERK1/2 and MEK, members
of the mitogen-activated protein kinase family, are down-
stream molecules of VEGFR and play critical roles in cell
growth. Protein kinase B (Akt) also mediates VEGFR sig-
naling via phosphatidylinositol 3-kinase and regulates cell
survival and proliferation. Even though ERK1/2, MEK,
and Akt were significantly activated by VEGF-C/VEGF-
D, sunitinib inhibited their phosphorylations (Figure 1c,
d; Additional file 1 and 2). Because the expression levels
of c-Raf and ras and the phosphorylation of c-Raf were
not significantly affected by sunitinib, other Rafs or med-
iators could be involved in this pathway (see Additional
data file 1).
To examine the contribution of VEGFR-2 in the sti-
mulation of the VEGFs, we used an anti-VEGFR2 anti-
body that specifically inhibits VEGFR-2 phosphorylation
(IC50 =1 . 6μg/ml) (see Additional data file 1, Figure
S1C). When we treated the LECs with anti-VEGFR-2
antibody at 2 μg/ml, VEGFR-2 phosphorylation was
r e d u c e dt oa l m o s tt h es a m el e v e la st h a to b s e r v e dw i t h
sunitinib treatment at 100 nM (Figure 1). Interestingly,
however, treatment with this antibody was not sufficient
to abolish downstream signaling, although the down-
stream signaling molecules were strongly suppressed by
sunitinib.
Sunitinib inhibited lymphatic endothelial cell growth
and cell functions. To analyze the cellular functions, we
first performed a growth-inhibition assay. Sunitinib inhib-
ited the growth of LECs induced by VEGF-C and VEGF-D
stimulation in a dose-dependent manner (Figure 2).
At 100 nM of sunitinib, the growth of the LECs was com-
pletely inhibited. Conversely, anti-VEGFR-2 antibody
(2 μg/ml) inhibited the cellular growth only partially.
Migration assay and tube-formation assay were then per-
formed. Transwell migration and capillary network forma-
tion of LECs were induced by VEGF-C, and sunitinib
inhibited both functions at a lower concentration (10 nM)
than that required for growth inhibition (Figure 3a). How-
ever, the inhibitory effects of anti-VEGFR-2 antibody treat-
ment (2 μg/ml) on both migration and tube formation
were weaker than those of sunitinib.
Sunitinib inhibited tumor growth in the m.f.p. model
To examine the effect of sunitinib on lymphangiogenesis
and metastasis, we used the mammary fat pad model with
a highly metastatic breast cancer cell line MDA-MB-
231LN. MDA-MB-231LN, which is engineered by trans-
fection of the firefly luciferase gene into the MDA-MB-
231 cell line, is a well-characterized model [26]. Before the
animal experiments, we evaluated the expression of
VEGFs in various types of metastatic cancer cell lines,
including breast (MDA-MB-231, MDA-MB-468, MDA-
MB-231LN), lung (A549, H226), and colon (HCT-116,
SW480) cancer (Figure 4a). MDA-MB-231 and MDA-
MB-231LN produce large amounts of VEGF-C and
VEGF-A. In some cell lines, the expression of VEGF-A
and VEGF-C was upregulated under hypoxic conditions.
We also tried to detect VEGF-D expression; however, the
amount of VEGF-D was below the limit of detection
under both hypoxic and normoxic conditions.
Then we inoculated MDA-MB-231LN expressing luci-
ferase into the m.f.p on the right side of the abdomen of
a female mouse, and treated it with sunitinib at 40 mg/
kg once a day, and DC101, an antibody for mouse
VEGFR-2, at 800 μg/mouse for 2 consecutive weeks. In
both groups of treated mice, tumor growth was signifi-
cantly impeded (Figure 4b).
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Next, we examined the effect of sunitinib on angiogenesis
and lymphangiogenesis by immunohistochemical analy-
sis. The density of blood vessels stained with anti-CD31
in the primary tumor was significantly reduced, to almost
the same degree, by treatment with sunitinib and DC101
(Figure 5a, b). The number of lymphatic vessels, stained
with anti-LYVE-1, was also reduced by this treatment.
Sunitinib was more potent than DC101 in reducing the
number of lymphatic vessels (Figure 5a, b).
Then, the lymph node metastases were analyzed by
bioluminescent imaging. Although previously, it was dif-
ficult to detect metastasis in living mice, development of
luciferase and the bioluminescent technology has now
enabled the detection of cancer cells in distant organs.
Bioluminescent signals from the primary tumor in the
m.f.p on the right side of the abdomen were observed on
day 0 (Figure 5c, left panel). Signals from the cells metas-
tasized around the axillary lymph node (right side) were
detected in all the mice of the control group at day 14
(Figure 5c, right panels). Metastasis in the lymph node
was confirmed by ex vivo imaging after resection. Lymph
node metastasis on the opposite side (left side) was also
observed in 6 mice from the control group; however, no
metastases were recognized in the mandibular or mesen-
teric lymph nodes (data not shown). Metastasis to the
axillary lymph node appears to occur in the early stage of
the metastatic phase in this model.
Sunitinib strongly inhibited the development of axil-
lary lymph node metastasis on the same side as the
tumor (right side), although some of the mice showed
metastasis (Table 1). Metastasis to the lung was also
reduced (Table 1, Additional data file 3). DC101 tended
Figure 1 Sunitinib blocked activation of VEGFR-2 and VEGFR-3 and their downstream molecules in human dermal LECs.L E C sw e r e
cultured to confluence, and the medium was replaced with a serum-free medium. After overnight incubation, the cells were pretreated with
sunitinib, anti-VEGFR2 antibody, or DMSO (controls), before being stimulated with 200 ng/ml VEGF-C (a) or VEGF-D (b). Lysates were
immunoprecipitated with VEGFR-3-specific antibody for phospho-VEGFR-3 detection (c, d). Other phosphoproteins were detected with their
respective specific antibodies. All samples were separated by 4% to 20% gradient SDS-PAGE gel. The proteins were blotted onto a PVDF
membrane and detected by Western blotting. Tyrosine phosphorylation of VEGFR-2 and VEGFR-3 was noted in the cells treated with VEGF-C or
VEGF-D. Sunitinib blocked phosphorylation of both VEGFR-3 and VEGFR-2, whereas anti-VEGFR-2 antibody inhibited phosphorylation of only
VEGFR-2. Increased phosphorylation of ERK1/2 and Akt was observed in the LECs stimulated with the VEGFs; however, this was attenuated in the
cells treated with sunitinib. DMSO, dimethyl sulfoxide; LEC, lymphatic endothelial cell; MW, molecular weight marker; VEGF, vascular endothelial
growth factor; VEGFR, vascular endothelial growth factor receptor.
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Page 5 of 11Figure 2 Sunitinib inhibited VEGF-induced proliferation of LECs. LECs were incubated in serum-free conditions in the absence or presence
of 500 ng/ml of VEGF-C (left) or VEGF-D (right), and DMSO or 10 to 300 nM sunitinib. The cellular proliferation was quantified by MTS assay after
7 days of treatment. Columns indicate the values in six replicates normalized to the nontreated controls; bars, SD. *P < 0.05 compared with
control. DMSO, dimethyl sulfoxide; LEC, lymphatic endothelial cell; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth
factor receptor.
Figure 3 Sunitinib inhibited VEGF-C-induced functions of LECs. (a) Quantification of LEC migration induced by VEGF-C in cells treated with
DMSO or 10 nmol/ml of sunitinib. Relative migration indicates the number of migrated cells normalized to the number of control cells. Columns
indicate the values from four experiments; bars, SD. *P < 0.05 as compared with control. Sunitinib suppressed VEGF-C-induced LEC migration. (b)
Photographs of VEGF-C-induced tube formation in cells treated with sunitinib or DMSO (control). VEGF-C promoted cord formation after overlay
of type I collagen, which was suppressed by sunitinib treatment, but not by anti-VEGFR2 antibody. The black line represents 200 μm. (c)
Quantification of tube formation. Columns indicate the values from the data of four fields; bars, SD. Sunitinib inhibited VEGF-C-induced tube
formation. *P < 0.05 as compared with control. DMSO, dimethyl sulfoxide; LEC, lymphatic endothelial cell; Suni, sunitinib; VEGF, vascular
endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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Page 6 of 11Figure 4 Expression of VEGF-C in various cancer cell lines; sunitinib inhibited MDA-MB-231LN tumor growth. (a) VEGF expression levels
were quantified in metastatic cancer cell lines under normoxic and hypoxic conditions. All cells were cultured overnight under normoxic or
hypoxic (5% O2) conditions; subsequently, the amounts of VEGFs secreted in the conditioned medium were quantified with enzyme-linked
immunosorbent assay (a). Columns indicate the values of four replicates; bars, SD. (b) Effects of sunitinib and of the anti-VEGFR-2 antibody,
DC101, on the primary tumor growth. MDA-MB-231LN cells were transplanted into the m.f.p. of female mice, and the treatment was initiated on
day 5 after the inoculation. Sunitinib was administered orally at 40 mg/kg once a day, and DC101 at 800 μg/mouse i.p. every 3 days for 2 weeks.
Tumor volume was measured on the indicated days. Points indicate tumor volume; bars, SEM. *P < 0.05 as compared with control. m.f.p.,
mammary fat pad; N.D., not detected; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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Page 7 of 11Figure 5 Sunitinib inhibited angiogenesis, lymphangiogenesis, and lymph node metastasis in the m.f.p. model. (a)
Immunohistochemical analysis of the primary tumor treated with sunitinib, DC101, or vehicle. Tumors were stained with anti-CD31 for
endothelial cells (upper) and anti-LYVE-1 for lymphatic endothelial cells (lower). Photographs were taken under a microscope at a magnification
of ×8. Photographs of representative areas are shown. The black line represents 50 μm. (b) Effects of sunitinib and DC101 on tumor
angiogenesis and lymphangiogenesis. The microvessel density (MVD, top) was determined by staining for CD31, and the lymphatic microvessel
density (LVD, bottom) by staining for LYVE-1. *P < 0.05 as compared with control. (c) Lymph node metastasis was detected by bioluminescent
imaging in vivo. The primary tumor (left) was identified on day 1 of treatment, and tumor metastasis around the axillary lymph node was
detected after treatment with vehicle control (right, upper) or sunitinib (right, lower). Ex vivo data of the lymph nodes confirmed metastasis from
the MDA-MB-231LN primary tumor. Three representative photographs from each treatment group are shown. LVD, lymphatic microvessel
density; m.f.p., mammary fat pad; MVD, microvessel density.
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compared with that of sunitinib.
Discussion
Sunitinib is well-known as an inhibitor of angiogenesis
a n dt oe x e r ta c t i v i t ya g a i n s tV E G F R 2 .I nt h i ss t u d y ,w e
demonstrated that sunitinib inhibited the activation of
VEGFR2/3 signaling and of the downstream molecules
MEK, Erk, and Akt induced by VEGF-C and VEGF-D in
lymphatic endothelial cells. Consequently, sunitinib
blocked the cellular functions of the LECs, such as
growth, migration and tube formation. Thus, sunitinib is
actually a dual inhibitor of VEGFR2 and VEGFR3.
VEGFR-3 plays a pivotal role in lymphatic vascular for-
mation, and VEGFR-3 inhibition by antibody has been
shown to disrupt the cellular functions of LECs and adult
lymphangiogenesis [18]. On the other hand, the role of
VRGFR2 in the development of lymphatic vessels is not
well clarified. However, VEGFR-2 is coexpressed and
forms a heterodimer with VEGFR-3 in lymphatic endothe-
lial cells [28] and the two molecules function together in
inducing angiogenic sprouting [29]. Consistent with this
mechanism, VEGFR2 and VEGFR3 in LECs are activated
concurrently by VEGFC/D stimulation. In addition, anti-
VEGFR2 antibody partially suppressed the functions of
LECs and tumor lymphangiogenesis in the mouse model.
VEGFR-2 could be involved in lymphangiogenesis through
its direct effect on the LECs. Collectively, suppression of
either VEGFR-2 or VEGFR-3 alone might not be sufficient
to inhibit cellular signaling and lymphangiogenesis. Other
multi-VEGFR inhibitors such as cediranib and PTK787
have also been demonstrated to show a suppressive effect
on lymphangiogenesis [23,24]. Similarly, the dual inhibi-
tion of VEGFR-2 and VEGFR-3 by sunitinib might be
important for the activity of this drug against the cellular
functions of LECs and lymphangiogenesis.
Our results of the animal experiment imply that suniti-
nib might be of benefit in the treatment of breast cancer
by suppressing lymph node metastasis. In clinical settings,
lymph node metastasis is a useful marker of the prognosis
of breast cancer and a determinant factor of systemic che-
motherapy in a neoadjuvant setting; moreover, lymph
node dissection prolongs the survival of patients with a
positive sentinel lymph node. The main mechanism
underlying this effect is thought to be suppression of the
formation of lymphatic vessels as escape routes to neigh-
boring lymph nodes. Furthermore, a new supportive role
of lymph nodes for cancer cell survival in lymphatic
organs has been proposed recently, and certain cancer
cells seem to move toward distant sites via lymph nodes in
the vicinity [5]. Given that the incidence of lung metastasis
was also reduced by sunitinib treatment, restricting metas-
tasis to regional lymph nodes might be useful to suppress
systemic dissemination.
VEGFR pathways are attractive targets in cancer thera-
peutics, since the activities of the ligands and receptors
can be controlled by specific antibodies or small-molecule
inhibitors, including sunitinib. Also, the invasion-promot-
ing role of VEGFRs in cancer cells has been reported
recently [30]. Actually, numerous studies have shown that
VEGFR inhibitors can suppress tumor growth and distant
metastasis [31,32]. However, recently, two groups have
also reported that short-term treatment with sunitinib
promotes metastasis in mice [33,34]. These previous data
and our present study data suggest that angiogenesis inhi-
bitors and angiogenic therapy could affect tumor metasta-
sis both positively and negatively depending on the drug
dosing schedule or the therapeutic setting, although the
precise underlying mechanisms remain unclear. Angiogen-
esis, lymphangiogenesis and metastasis are intricate pro-
cesses involving not only numerous molecules, but also
various physiologic responses. These mechanisms should
be further investigated to develop better therapeutic use of
inhibitors of angiogenesis and lymphangiogenesis.
Conclusions
In this study, we demonstrated that sunitinib inhibited
VEGFR-3 and VEGFR-2 signaling under VEGF-C or
VEGF-D stimulation, and that it interfered with the cellu-
lar functions of LECs induced by VEGF-C, thereby inhi-
biting lymphangiogenesis and lymph node metastasis in a
breast cancer model. In particular, we showed that inhi-
bition of VEGFR-3 might be essential for these effects of
sunitinib. Our findings suggest that sunitinib might be of
benefit in the treatment of breast cancer by suppressing
lymphangiogenesis and lymph node metastasis.
Additional material
Additional file 1: Figure S1. effect of sunitinib on the signaling
molecules ras, c-Raf, and MEK in the LECs, and the dose-dependent
effect of anti-VEGFR-2 on VEGFR-2 phosphorylation. Western blotting
was performed, as shown in Figure 1. Although sunitinib did not affect
the degree of phosphorylation of ras or c-Raf, it suppressed MEK
phosphorylation (a). LECs were treated with anti-VEGFR-2 (0, 0.2, 2. or 5
Table 1 Effect of sunitinib and DC101 on axillary lymph
node and lung metastasis from MDA-MB-231LN in the m.
f.p. model
Treatment Axillary lymph node metastases (right,
left)
Lung
metastases
Control 14/14 (13, 6) 12/14
DC101 10/15 (10, 1) 9/15
Sunitinib 5/15
a (5, 0) 3/15
a
In the experiment illustrated in Figure 5, axillary lymph node and lung
metastases were confirmed by bioluminescent imaging ex vivo. Values are
shown as the number of mice with metastasis in each organ. The statistical
analysis is described in the Materials and Methods section. The results were
considered to be statistically significant at P < 0.05.
aP < 0.05 as compared
with control.
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Page 9 of 11μg) under VEGF-C stimulation (b). The inhibitory effect of the antibody
was saturated at the antibody dose of 2 μg.
Additional file 2: Figure S2. Quantification of protein
phosphorylations induced by VEGF-C/D. Western blotting data (Figure
1) were captured and quantified by the imaging software, MultiGauge
(Fujifilm). The amounts of phosphorylated protein were divided by those
of total protein. Each phosphorylation ratio was normalized to that in the
nontreated controls.
Additional file 3: Figure S3. Lung metastasis was detected after
treatment with vehicle control (upper) or sunitinib (lower).
Representative photographs of three ex vivo data from each treatment
group are shown.
Abbreviations
DMSO: dimethyl sulfoxide; ERK1/2: extracellular signal-regulated kinase 1/2;
LEC: lymphatic endothelial cell; m.f.p: mammary fat pad; VEGF: vascular
endothelial growth factor; VEGFR: vascular endothelial growth factor
receptor.
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